SCHEDULE: Armistice Capital Amends Moleculin Biotech Stake

Armistice Capital and Steven Boyd updated their beneficial ownership in Moleculin Biotech, Inc., reporting a 4.99% stake.

Summary

• Armistice Capital, LLC and Steven Boyd filed an Amendment No. 4 to their Schedule 13G regarding Moleculin Biotech, Inc. common stock.
• The reporting persons collectively beneficially own 1,586,521 shares of Moleculin Biotech, Inc. common stock.
• This ownership represents 4.99% of the issuer's class of securities.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 1,586,521 shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a biotechnology company, providing transparency on significant shareholder stakes within the industry.

Related Party Transactions

• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. This relationship defines the beneficial ownership.

Stakeholder Impact

• Shareholders receive updated information on the beneficial ownership stake held by Armistice Capital, LLC and Steven Boyd, providing transparency on significant holders.

Key Dates

Keywords

Moleculin Biotech, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotech